The final patient completing our pivotal F351 Phase 3 trial marks an important milestone for Gyre and our development pipeline. We are grateful to the patients, researchers, trial investigators, and ...

BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological ...

Milk thistle, known for its silymarin content, is celebrated for protecting the liver against damage, reducing inflammation, ...

Mice and ticks can endanger the health of you and your family, but you could inadvertently be inviting them into your yard ...

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

Cardiovascular disease (CVD) is the leading cause of death globally ... We’re working on new delivery systems for RNAi ...

Lipoproteins circulate throughout the body. You may have looked at your blood test results and wondered what they do. Find ...

Even if you’re not experiencing any GI symptoms right now, certain habits can help ensure your gut stays in tip-top shape.

Last week, BioVie announced a significant milestone: a Notice of Allowance from the Japan Patent Office for its application regarding a novel liquid formulation of terlipressin. This formulation, ...

A group of researchers at VCU Massey Comprehensive Cancer Center was awarded $13 million by the National Cancer Institute.

Chronic and acute graft-versus-host disease are managed differently, affect different organs, and impact patients in ...